Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

A flurry of executive orders and other actions Trump issued on his first day back in office included rescinding directives by his predecessor, former President Joe Biden, that had promoted lowering drug costs and expanding coverage under the Affordable Care Act and Medicaid.

Upon his return to the United States Presidency, Donald Trump signed a number of executive orders that will not have an immediate impact, but will take effect in the coming weeks.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate, but if they don’t, they face fines or the possible end of Medicare reimbursements.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Biden’s domestic policy adviser says Trump avoided pledges to overhaul the Affordable Care Act and other health programs — but changes are coming anyway.